Joseph Ramelli

Cytori Therapeutics: Soon to Be Sold to Olympus?

"Gross margins were up 20% sequentially to 72% during 3Q08 thanks to cost-cutting in the form of reduced R&D + G&A expense, offset by higher marketing costs since the 1Q08 launch of the Celution System."

Gross margins are calculated before R&D and G&A and thus would not benefit from reductions in these expenses. This is accounting 101 stuff. No offense, but you should really understand this before posting an article on seekingalpha.